ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $32.13 billion. The enterprise value is $33.15 billion.
| Market Cap | 32.13B |
| Enterprise Value | 33.15B |
Important Dates
The last earnings date was Thursday, April 25, 2024, after market close.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | May 8, 2024 |
Share Statistics
ResMed has 146.91 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Shares Outstanding | 146.91M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 58.26% |
| Float | 145.49M |
Valuation Ratios
The trailing PE ratio is 33.68 and the forward PE ratio is 26.53. ResMed's PEG ratio is 1.75.
| PE Ratio | 33.68 |
| Forward PE | 26.53 |
| PS Ratio | 7.03 |
| Forward PS | 6.65 |
| PB Ratio | 6.96 |
| P/FCF Ratio | 29.57 |
| PEG Ratio | 1.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.78, with an EV/FCF ratio of 30.43.
| EV / Earnings | 34.59 |
| EV / Sales | 7.23 |
| EV / EBITDA | 22.78 |
| EV / EBIT | 26.77 |
| EV / FCF | 30.43 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.25.
| Current Ratio | 3.04 |
| Quick Ratio | 1.32 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.07 |
| Interest Coverage | 22.63 |
Financial Efficiency
Return on equity (ROE) is 21.90% and return on invested capital (ROIC) is 16.95%.
| Return on Equity (ROE) | 21.90% |
| Return on Assets (ROA) | 14.10% |
| Return on Capital (ROIC) | 16.95% |
| Revenue Per Employee | $452,087 |
| Profits Per Employee | $94,515 |
| Employee Count | 10,140 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, ResMed has paid $225.49 million in taxes.
| Income Tax | 225.49M |
| Effective Tax Rate | 19.05% |
Stock Price Statistics
The stock price has decreased by -3.30% in the last 52 weeks. The beta is 0.64, so ResMed's price volatility has been lower than the market average.
| Beta (1Y) | 0.64 |
| 52-Week Price Change | -3.30% |
| 50-Day Moving Average | 198.11 |
| 200-Day Moving Average | 172.03 |
| Relative Strength Index (RSI) | 62.73 |
| Average Volume (30 Days) | 1,103,320 |
Short Selling Information
The latest short interest is 9.85 million, so 6.70% of the outstanding shares have been sold short.
| Short Interest | 9.85M |
| Short Previous Month | 7.89M |
| Short % of Shares Out | 6.70% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 7.42 |
Income Statement
In the last 12 months, ResMed had revenue of $4.58 billion and earned $958.38 million in profits. Earnings per share was $6.51.
| Revenue | 4.58B |
| Gross Profit | 2.56B |
| Operating Income | 1.21B |
| Pretax Income | 1.18B |
| Net Income | 958.38M |
| EBITDA | 1.46B |
| EBIT | 1.24B |
| Earnings Per Share (EPS) | $6.51 |
Balance Sheet
The company has $237.91 million in cash and $1.17 billion in debt, giving a net cash position of -$929.54 million or -$6.33 per share.
| Cash & Cash Equivalents | 237.91M |
| Total Debt | 1.17B |
| Net Cash | -929.54M |
| Net Cash Per Share | -$6.33 |
| Equity / Book Value | 4.63B |
| Book Value Per Share | 31.52 |
| Working Capital | 1.58B |
Cash Flow
In the last 12 months, operating cash flow was $1.20 billion and capital expenditures -$109.03 million, giving a free cash flow of $1.09 billion.
| Operating Cash Flow | 1.20B |
| Capital Expenditures | -109.03M |
| Free Cash Flow | 1.09B |
| FCF Per Share | $7.41 |
Margins
Gross margin is 55.78%, with operating and profit margins of 26.48% and 20.91%.
| Gross Margin | 55.78% |
| Operating Margin | 26.48% |
| Pretax Margin | 25.83% |
| Profit Margin | 20.91% |
| EBITDA Margin | 31.75% |
| EBIT Margin | 27.02% |
| FCF Margin | 23.77% |
Dividends & Yields
This stock pays an annual dividend of $1.92, which amounts to a dividend yield of 0.88%.
| Dividend Per Share | $1.92 |
| Dividend Yield | 0.88% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 12 |
| Payout Ratio | 29.49% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 0.84% |
| Earnings Yield | 2.97% |
| FCF Yield | 3.38% |
Analyst Forecast
The average price target for ResMed is $212.30, which is -2.94% lower than the current price. The consensus rating is "Buy".
| Price Target | $212.30 |
| Price Target Difference | -2.94% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 8.63% |
| EPS Growth Forecast (5Y) | 13.70% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 11.38 and a Piotroski F-Score of 5.
| Altman Z-Score | 11.38 |
| Piotroski F-Score | 5 |